Abstract
BackgroundWe evaluated the effects of cytochrome P450 3A4 (CYP3A4) induction and inhibition on steady-state pharmacokinetics of the components of a novel oral contraceptive (OC) containing estradiol valerate (E2V) and dienogest (DNG). Study DesignCYP3A4 induction was assessed in an open-label, one-arm study. Sixteen healthy postmenopausal women received E2V 2 mg/DNG 3 mg (days 1–17) and concomitant rifampicin (600 mg, days 12–16). Ratios of the area under the serum concentration–time curve between 0 and 24 h [AUC(0–24 h)] and maximum serum concentration (Cmax) of E2 and DNG on days 17 and 11 (after and before rifampicin intervention) are presented. CYP3A4 inhibition was investigated in an open-label, parallel-group study in 24 healthy postmenopausal women receiving E2V 2 mg/DNG 3 mg (days 1–14) and concomitant ketoconazole (400 mg, n=12) or erythromycin (500 mg three times daily, n=12) on days 8–14. Mean ratios of AUC(0–24 h) and Cmax of E2 and DNG on days 7 and 14 are presented. ResultsConcomitant administration of rifampicin decreased systemic drug exposure and yielded geometric mean ratios for E2Cmax and AUC(0–24 h) of 75% and 56%, respectively. Corresponding mean ratios for DNG were 48% and 17%, respectively. Ketoconazole coadministration increased systemic drug exposure and yielded ratios of E2 of 165% and 157%, respectively, and ratios of DNG of 194% and 286%, respectively. Erythromycin coadministration also resulted in increased mean Cmax and AUC(0–24 h) of both E2 and DNG. Geometric mean ratios of Cmax and AUC(0–24 h) for E2 were 151% and 133%, respectively. Corresponding ratios for DNG were 133% and 162%, respectively. ConclusionsSignificant drug–drug interactions are apparent when CYP3A4 modulators are coadministered with the components of a novel OC containing E2V/DNG. Coadministration of CYP3A4 modulators should be avoided where possible, and another type of contraception should be used when coadministration of CYP3A4 inducers like rifampicin is unavoidable.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have